Synapse - Chau Dang

Results (273)

Effects of exercise therapy dosing schedule on impaired cardiorespiratory fitness in patients with primary breast cancer: A randomized controlled trial

Journal Article

Scott, J. M.; Thomas, S. M.; Peppercorn, J. M.; Herndon, J. E. 2nd; Douglas, P. S.; Khouri, M. G.; Dang, C. T.; Yu, A. F.; Catalina, D.; Ciolino, C.; more...
Circulation (2020)

Fulltext@MSK | Save

Neoadjuvant treatment in breast cancer

Book Section

Wang, R.; Dang, C.
In Urban, C.; Rietjens, M.; El-Tamer, M.; Sacchini, V. S. (Eds.) Oncoplastic and Reconstructive Breast Surgery. 2nd ed (2019)

Fulltext@MSK | Save

Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial

Journal Article

Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
JAMA Network Open (2019)

Fulltext@MSK | Save

Effects of non-linear or linear aerobic training (AT) dosing regimens on impaired cardiovascular (CV) function in patients with operable breast cancer: A randomized controlled trial (RCT)

Meeting Abstract

Scott, J.; Thomas, S. M.; Herndon, J. E.; Peppercorn, J. M.; Douglas, P. S.; Khouri, M.; Dang, C. T.; Yu, A. F.; Catalina, D.; Ciolino, C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC)

Meeting Abstract

dos Anjos, C. H.; Razavi, P.; Herbert, J.; Colon, J.; Gill, K.; Modi, S.; Bromberg, J.; Dang, C. T.; Liu, D.; Norton, L.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Risk stratification and daily symptom monitoring for oncology patients

Meeting Abstract

Daly, R. M.; Perry, C.; Chiu, Y. O.; Katzen, L. L.; Rozenshteyn, M.; Kuperman, G.; Dhami, A. K.; Salvaggio, R.; Baldwin, A.; Holland, J. C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinicopathologic features of breast cancers with HER2/CEP17 ratio < 2, HER2 copy number ≥ 4 and < 6 signals/cell

Meeting Abstract

Xu, J.; Brogi, E.; Ventura, K.; Ross, D.; Dang, C.; Robson, M.; Norton, L.; Morrow, M.; Wen, H.
Modern Pathology (2019)

Fulltext@MSK | Save

Impact of the 2018 ASCO/CAP HER2 guideline updates on HER2 assessment in breast cancer with HER2 immunohistochemistry equivocal results

Meeting Abstract

Wen, H.; Ventura, K.; Xu, J.; Ross, D.; Dang, C.; Robson, M.; Norton, L.; Morrow, M.; Brogi, E.
Modern Pathology (2019)

Fulltext@MSK | Save

Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer

Journal Article

Tolaney, S. M.; Guo, H.; Pernas, S.; Barry, W. T.; Dillon, D. A.; Ritterhouse, L.; Schneider, B. P.; Shen, F.; Fuhrman, K.; Baltay, M.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinicopathologic features of breast cancers with HER2/CEP17 ratio <2, HER2 copy number ≥ 4 and <6 signals/cell

Meeting Abstract

Xu, J.; Brogi, E.; Ventura, K.; Ross, D.; Dang, C.; Robson, M.; Norton, L.; Morrow, M.; Wen, H.
Laboratory Investigation (2019)

Fulltext@MSK | Save